Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C18H26FN3O3 |
| Molecular Weight | 351.4157 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)C12CCC(CC1)(CC2)NCC(=O)N3C[C@@H](F)C[C@H]3C#N
InChI
InChIKey=AKFNKZFJBFQFAA-DIOPXHOYSA-N
InChI=1S/C18H26FN3O3/c1-2-25-16(24)17-3-6-18(7-4-17,8-5-17)21-11-15(23)22-12-13(19)9-14(22)10-20/h13-14,21H,2-9,11-12H2,1H3/t13-,14-,17?,18?/m0/s1
| Molecular Formula | C18H26FN3O3 |
| Molecular Weight | 351.4157 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Bisegliptin (also known as KRP-104) was developed as an orally active dipeptidyl peptidase IV (DPPIV) inhibitor. It is known, that DPPIV inhibition reduces blood glucose through suppression of the degradation of the insulin-releasing hormone. Bisegliptin successfully completed the phase II clinical trials for patients with type 2 diabetes. However, further development of the drug has been discontinued for business reason. The company wasn’t able to find a tie-up partner to co-develop.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00995345
Tablet, once-daily for 24 weeks
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:41:42 GMT 2025
by
admin
on
Mon Mar 31 19:41:42 GMT 2025
|
| Record UNII |
9U5KQ79OK6
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C171768
Created by
admin on Mon Mar 31 19:41:42 GMT 2025 , Edited by admin on Mon Mar 31 19:41:42 GMT 2025
|
PRIMARY | |||
|
100000175105
Created by
admin on Mon Mar 31 19:41:42 GMT 2025 , Edited by admin on Mon Mar 31 19:41:42 GMT 2025
|
PRIMARY | |||
|
862501-61-9
Created by
admin on Mon Mar 31 19:41:42 GMT 2025 , Edited by admin on Mon Mar 31 19:41:42 GMT 2025
|
PRIMARY | |||
|
11688894
Created by
admin on Mon Mar 31 19:41:42 GMT 2025 , Edited by admin on Mon Mar 31 19:41:42 GMT 2025
|
PRIMARY | |||
|
DB06127
Created by
admin on Mon Mar 31 19:41:42 GMT 2025 , Edited by admin on Mon Mar 31 19:41:42 GMT 2025
|
PRIMARY | |||
|
9350
Created by
admin on Mon Mar 31 19:41:42 GMT 2025 , Edited by admin on Mon Mar 31 19:41:42 GMT 2025
|
PRIMARY | |||
|
9U5KQ79OK6
Created by
admin on Mon Mar 31 19:41:42 GMT 2025 , Edited by admin on Mon Mar 31 19:41:42 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |